Published online before print April 10, 2008

This Article Full Text Full Text (PDF) All Versions of this Article: jmoldx.2008.070178v1 10/3/242    most recent Purchase Article View Shopping Cart Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Li, A. R. Articles by Ladanyi, M. Search for Related Content PubMed PubMed Citation Articles by Li, A. R. Articles by Ladanyi, M.

Journal of Molecular Diagnostics 2008, Vol. 10, No. 3
Copyright © 2008 American Society for Investigative Pathology & Association for Molecular Pathology
DOI: 10.2353/jmoldx.2008.070178

EGFR Mutations in Lung Adenocarcinomas

Clinical Testing Experience and Relationship to EGFR Gene Copy Number and Immunohistochemical Expression

Allan R. Li^*, Dhananjay Chitale^*, Gregory J. Riely, William Pao, Vincent A. Miller, Maureen F. Zakowski^*, Valerie Rusch, Mark G. Kris and Marc Ladanyi^*

From the Departments of Pathology, * Medicine, and Surgery, and the Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, New York

Lung adenocarcinomas responsive to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors possess EGFR mutations and often increased EGFR copy number. We prospectively studied 334 clinical cases using polymerase chain reaction-based assays to detect deletions within exon 19 and the L858R mutation in exon 21, which together account for approximately 90% of EGFR mutations. Seventy-eight (23%) of these tumors had an EGFR mutation, with 55 (71%) exon 19 deletions and 23 (29%) exon 21 L858R mutations. We were able to compare mutant and normal EGFR alleles and found a preferential amplification of the mutant allele. The association of mutations with EGFR amplification (determined by chromogenic in situ hybridization) and EGFR expression (determined by immunohistochemistry) was further examined in a subset of 60 tumors. EGFR amplification (5 EGFR signals per nucleus) was seen in 15 of 29 (52%) EGFR-mutated tumors but in only five of 31 (6%) non-mutated tumors (P = 0.006). EGFR overexpression was strongly associated with amplification but was statistically independent of EGFR mutation. Most patients with EGFR mutations (17 of 29, 59%) never smoked compared with 13% (four of 31) of patients lacking such mutations (P = 0.0003). The association of amplification with smoking status was marginal and was nonexistent with EGFR expression. Thus, these results indicate that EGFR amplification, preferentially of the mutant allele, often accompanies EGFR mutation, whereas EGFR immunohistochemical staining associates with amplification but cannot predict EGFR mutation status.

This article has been cited by other articles:

				J. Yu, S. Kane, J. Wu, E. Benedettini, D. Li, C. Reeves, G. Innocenti, R. Wetzel, K. Crosby, A. Becker, et al. Mutation-Specific Antibodies for the Detection of EGFR Mutations in Non-Small-Cell Lung Cancer Clin. Cancer Res., May 1, 2009; 15(9): 3023 - 3028. [Abstract] [Full Text] [PDF]

				G. J. Riely and M. Ladanyi KRAS Mutations: An Old Oncogene Becomes a New Predictive Biomarker J. Mol. Diagn., November 1, 2008; 10(6): 493 - 495. [Abstract] [Full Text] [PDF]